9FX.F Zhaoke Ophthalmology Limited
- Market cap
- EUR 119M
- P/E
- -
- P/B
- 0.64x
- ROE
- -13.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 9FX.F undervalued?
Graham numberThe Graham number of Zhaoke Ophthalmology Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhaoke Ophthalmology Limited fundamental analysis
No fundamental analysis for Zhaoke Ophthalmology Limited yet.
Zhaoke Ophthalmology Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in…
Full company profileZhaoke Ophthalmology Limited financial statements
Zhaoke Ophthalmology Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 18.8M | 69.3M | 32.0M |
| Gross Profit | - | 0.00 | 14.2M | 51.8M | 16.1M |
| Operating Income | -396M | -406M | -452M | -286M | -275M |
| EBITDA | - | -369M | -328M | -174M | -148M |
| Net Income | -2.13B | -407M | -385M | -237M | -209M |
| EPS | -3.93 | -0.75 | -0.71 | -0.43 | -0.38 |
| Balance Sheet | |||||
| Total Assets | 2.61B | 2.57B | 2.42B | 2.24B | 1.94B |
| Total Liabilities | 110M | 222M | 372M | 343M | 359M |
| Shareholders' Equity | 2.50B | 2.35B | 2.05B | 1.90B | 1.58B |
| Cash & Short-term Investments | 2.13B | 1.72B | 1.46B | 1.12B | 959M |
| Cash Flow | |||||
| Operating Cash Flow | -245M | -331M | -324M | -254M | -260M |
| Capital Expenditure | 94.5M | 239M | 95.3M | 44.1M | 4.84M |
| Free Cash Flow | -340M | -570M | -419M | -298M | -265M |
| Ratios | |||||
| ROE | -85.3% | -17.3% | -18.8% | -12.5% | -13.3% |
| ROA | -81.7% | -15.8% | -15.9% | -10.6% | -10.8% |
| Net Profit Margin | - | - | -2,053.5% | -342.6% | -653.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zhaoke Ophthalmology Limited dividends
Zhaoke Ophthalmology Limited has not paid dividends in the last 5 fiscal years.
Who owns Zhaoke Ophthalmology Limited
- Insiders 30.51%
- Institutions 11.46%
- Public & others 58.03%
- Shares outstanding 547M
- Free float 348M
Zhaoke Ophthalmology Limited company profile
- Company name
- Zhaoke Ophthalmology Limited
- Ticker
- 9FX.F
- ISIN
- KYG989M51017
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 285
- Fiscal year end
- December
- Address
- No. 1 Meide 3rd Road, Guangzhou, China
- Phone
- 86 20 3906 2828
- Website
- zkoph.com
About Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow myopia progression in children and adolescents; BRIMOCHOL PF and Carbachol PF pupil-modulating eye drops to correct for the loss of near vision associated with presbyopia; TAB014, a clinical-stage bevacizumab-based antibody indicated for wAMD; and PAN-90806 a drug indicated in the treatment of wAMD and DME. In addition, the company develops ZK002, a protein with a novel mechanism of action to contain inflammation and vascular flood leakage; Bimatoprost, a generic drug used in the treatment of glaucoma; Levobetaxolol HCl, a generic eye drop used in the treatment of glaucoma to lower pressure in the eye; and Travoprost, a prescribed PGAs for open-angle glaucoma. Further, it is involved in the development of Bimatoprost Timolol for targeting glaucoma; Latanoprost Timolol, a PGA and ß blocker combination eye drop targeting glaucoma; Travoprost Timolol, a potential first-to-market generic travoprost timolol; and Latanoprost, a prescribed PGAs for open-angle glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.
Zhaoke Ophthalmology Limited management
9- Dr. Xiaoyi Li Ph.D.CEO & Executive Chairman of the Board · born 1963
- Mr. Xiangrong DaiCOO & Executive Director · born 1980
- Dr. Lit Fui LauPresident & Chief Scientific Officer · born 1963
- Ms. Yang LeiGroup General Counsel · born 1981
- Dr. Mauro Bove Ph.D.Senior Vice President of Corporate Development · born 1955
- Mr. Jiang FengSenior Vice President of Sales & Marketing · born 1976
- Mr. Guohui ZhangSenior Vice President of Manufacturing & Logistics · born 1974
- Ms. Carol LiuGroup Head of Regulatory Affairs · born 1984
- Ms. Suk Yan Yau CPAVP of Financial Dept. & Company Secretary · born 1982